بيجن

Bigen Acquires Abilis for $5.6 Billion to Enhance Kidney Treatments

Bigen has announced its acquisition of Abilis Pharmaceuticals for <strong>$5.6 billion</strong>, aiming to expand its portfolio in immunology and rare diseases. This acquisition is one of the largest in the company's history.